Post-Anesthetic Apnea due to Butyrylcholinesterase (BCHE) Deficiency

Post-anesthetic apnea due to BCHE deficiency means a person has a much slower breakdown of certain anesthesia muscle-relaxing drugs—mainly succinylcholine (also called suxamethonium) and mivacurium. These drugs are usually removed from the body within minutes by an enzyme in the blood called butyrylcholinesterase (also named pseudocholinesterase). When the enzyme is missing, reduced, or works poorly, the drugs last far longer than expected. As a result, after surgery the person can stay paralyzed and not breathing on their own for a long time and needs help with breathing until the medicines wear off. This reaction is typically discovered after anesthesia the first time someone receives one of these drugs. NCBI+2MedlinePlus+2

Post-anesthetic apnea due to BCHE (pseudocholinesterase) deficiency means breathing stops or becomes very weak after anesthesia because the body cannot break down certain muscle-relaxing medicines, especially succinylcholine and mivacurium. These drugs are normally broken down quickly by an enzyme in the blood called butyrylcholinesterase (also called pseudocholinesterase). If the enzyme is low or works poorly, the drugs last much longer than expected. This causes prolonged paralysis and trouble breathing until the drugs naturally wear off or are reversed. The problem can be inherited (changes in the BCHE gene) or acquired (enzyme levels drop in some illnesses, pregnancy, or with certain medicines). The main treatment is airway support and mechanical ventilation until the muscles recover; future prevention is to avoid succinylcholine and mivacurium and use alternatives. NCBI+2MedlinePlus+2

Other names

This condition appears under several names in charts, lab reports, or articles:

• Pseudocholinesterase deficiency (the most common name). NCBI

• Butyrylcholinesterase (BChE/BCHE) deficiency or low plasma cholinesterase. NCBI

• Atypical cholinesterase or low dibucaine number (based on a classic lab test). OpenAnesthesia

• Succinylcholine apnea / suxamethonium apnea (describes the effect). ScienceDirect

Types

1) Inherited (genetic) BCHE deficiency.
This is usually autosomal recessive. Different gene variants reduce enzyme activity. Classic variants identified by testing include “atypical (A), fluoride-resistant (F), silent (S), Kalow (K), and J variants.” People with two strong variants can have very long paralysis after succinylcholine; people with one variant have a milder or borderline reaction. PMC+1

2) Acquired (temporary or secondary) reduction in BCHE.
Here the gene is normal, but enzyme levels fall due to illness, injury, or medicines—making a person more sensitive to succinylcholine or mivacurium at that time. When the condition resolves, enzyme activity can return toward normal. NCBI

Causes

1. BCHE gene variants (inherited). Variants change the structure or amount of enzyme so it cannot break down succinylcholine or mivacurium quickly. PMC

2. Heterozygous carrier state. One altered gene can still lower activity enough to prolong recovery modestly, especially with higher doses. OpenAnesthesia

3. Severe liver disease. The enzyme is made in the liver; damaged liver makes less, so drugs last longer. NCBI

4. Pregnancy and early postpartum. Enzyme levels naturally fall, increasing sensitivity during this period. NCBI

5. Burns and major trauma. These states reduce enzyme activity and also change drug handling. ScienceDirect

6. Malnutrition or major weight loss. Less protein production means lower enzyme output. NCBI

7. Kidney failure. Uremia and illness stress reduce enzyme activity. NCBI

8. Cancer and severe infections. Illness reduces plasma enzyme production. NCBI

9. Organophosphate exposure (e.g., some pesticides). These chemicals inhibit cholinesterases and can dramatically prolong paralysis. NCBI

10. Anticholinesterase eye drops (e.g., echothiophate). Even topical use can suppress enzyme activity and prolong succinylcholine effect. NCBI

11. Certain chemotherapy drugs (e.g., cyclophosphamide). Can decrease enzyme levels and extend drug action. NCBI

12. Metoclopramide and some antidepressants. Reported to reduce pseudocholinesterase activity. NCBI

13. Estrogens/oral contraceptives. May lower activity modestly; effect is usually small but relevant with succinylcholine. NCBI

14. Plasmapheresis or massive transfusion. Dilutes plasma proteins, including the enzyme. NCBI

15. Hypothyroidism or severe endocrine illness. Can reduce liver protein output, including this enzyme. NCBI

16. Advanced age. Some older adults show lower activity, increasing risk if given succinylcholine. NCBI

17. Chronic alcoholism or substance use. Associated with altered liver protein synthesis. NCBI

18. Inflammation and critical illness. Acute-phase responses can suppress nonessential plasma proteins like BCHE. NCBI

19. Genetic “silent” variants. Extremely low or absent enzyme activity causes very long paralysis after usual doses. PMC

20. Unknown/undetected factors. Sometimes no clear cause is found until formal enzyme and gene testing is done. NCBI

Common signs and symptoms

These are not symptoms of daily life. They appear after anesthesia when succinylcholine or mivacurium were used.

1. Not waking up with normal muscle strength on time. The person stays weak long after surgery finishes. MedlinePlus

2. Not breathing on their own (apnea). A ventilator or breathing bag is needed for hours. MedlinePlus

3. Very weak breathing or small breaths. Tidal volumes are too low without help. NCBI

4. Unable to move arms and legs. Paralysis is prolonged beyond the expected window. MedlinePlus

5. Cannot open eyes or lift head when otherwise awake. Classic sign of ongoing neuromuscular block. PMC

6. Train-of-four fade on nerve monitor. Objective signs show incomplete recovery. asahq.org

7. Low oxygen levels if support is removed too early. Pulse oximetry can drop quickly. PMC

8. Need for extended recovery or ICU time. Monitoring continues until full strength returns. NCBI

9. Possible anxiety or awareness with paralysis (rare). If sedation wears off before paralysis, patients can be awake but unable to move; teams work hard to prevent this. PMC

10. Sore throat from prolonged intubation. Because the breathing tube stays longer. NCBI

11. Temporary double vision or weak eye muscles. Small muscles recover last. PMC

12. Difficulty coughing and clearing secretions. Until muscle power returns. PMC

13. Delayed discharge. Full strength must be documented before going home. Cureus

14. No long-term weakness once the drug wears off. The issue is time-limited; the enzyme problem does not cause daily paralysis. MedlinePlus

15. Recurs with future exposure unless avoided. If succinylcholine or mivacurium are used again, the same reaction can happen. NCBI

Diagnostic tests

A) Physical examination and bedside observation

1. Airway and breathing check (post-op). The team looks for normal chest rise, adequate breaths, and safe oxygen levels; if these are not present without support, ongoing block is suspected. PMC

2. Consciousness and movement check. If the patient is alert enough but still cannot move or lift their head, paralysis is likely still present. PMC

3. Vital signs and oxygen saturation. Pulse oximetry tracks oxygen safely while recovery continues. PMC

4. Respiratory effort signs. Shallow breathing or use of the ventilator’s full support suggests incomplete recovery. PMC

5. Secretions and cough strength. Weak cough points to residual block and the need to delay extubation. PMC

B) Manual neuromuscular tests (qualitative monitors used at the bedside)

6. Peripheral nerve stimulator—train-of-four (TOF) by feel/visual. The clinician stimulates the ulnar or facial nerve and feels or sees the twitches. “Fade” means persistent block. This simple tool helps detect residual paralysis. PMC

7. Sustained tetanic response (qualitative). A 50-Hz stimulus is applied; inability to sustain a strong response indicates block. PMC

8. Five-second head-lift (when awake) or sustained hand-grip. Classic bedside signs; if the patient cannot perform these reliably, full recovery has not occurred. Quantitative devices are still preferred. PMC

9. Double-burst stimulation (qualitative). Two short bursts help the clinician perceive “fade” better than TOF alone. PMC

C) Laboratory and pathological tests

10. Serum pseudocholinesterase (butyrylcholinesterase) activity. A blood test measures the enzyme level/activity; low values support the diagnosis. NCBI

11. Dibucaine number. Dibucaine (a local anesthetic) normally inhibits this enzyme. The percent inhibition is reported as the “dibucaine number”: ~80% is typical; 50–60% suggests a heterozygous variant; 20–30% suggests a homozygous strong variant. OpenAnesthesia

12. Fluoride number. Analogous inhibition testing with fluoride helps identify fluoride-resistant variants. Radius Anesthesia of Michigan

13. BCHE gene testing (sequencing or targeted panels). Confirms the genetic cause and helps with family counseling. PMC

14. Arterial blood gas (ABG). If ventilation is inadequate, ABG shows high CO₂ and low oxygen without support, guiding safe ventilation. PMC

15. Liver function tests and albumin. Low values can explain an acquired reduction of enzyme production. NCBI

16. Pregnancy testing (when appropriate). Helps explain a temporary fall in enzyme activity. NCBI

17. Medication and toxin review (including pesticides). A careful chart and exposure review can identify enzyme inhibitors. NCBI

D) Electrodiagnostic / quantitative neuromuscular monitoring

18. Quantitative acceleromyography (TOF ratio). A device measures twitch strength and calculates the TOF ratio. Safe recovery is usually TOF ratio ≥ 0.9 at the adductor pollicis. Guidelines strongly recommend quantitative monitoring rather than only qualitative checks. asahq.org+1

19. Electromyography-based monitors. EMG sensors measure true muscle response to nerve stimulation and help confirm full reversal before extubation. bjaed.org

E) Imaging tests (used to assess complications, not to diagnose the enzyme problem itself)

20. Chest X-ray (and, rarely, lung ultrasound/CT). If breathing is weak for long, imaging can look for atelectasis or aspiration while ventilatory support continues. Imaging does not diagnose BCHE deficiency; it checks for problems caused by prolonged weakness. PMC

Core treatment

The mainstay is airway and breathing support until the muscle relaxant wears off. That means endotracheal intubation, mechanical ventilation, oxygen, sedation/analgesia, and careful neuromuscular monitoring. If a non-depolarizing blocker (like rocuronium) was used, sugammadex can rapidly reverse it. If older non-depolarizing agents were used, neostigmine with an antimuscarinic (e.g., glycopyrrolate) can help. Do not give more succinylcholine. For rare severe cases, fresh frozen plasma (FFP) or whole blood can provide enzyme and speed recovery, but most patients recover with supportive care alone. Medscape+2accessdata.fda.gov+2

---

Non-pharmacological treatments

Note: For each item I give a short description, purpose, and mechanism in plain language.

1. Immediate airway support and oxygen.
   Purpose: keep oxygen levels safe. Mechanism: oxygen and airway maneuvers maintain gas exchange while drug effect persists. Medscape

2. Endotracheal intubation and mechanical ventilation.
   Purpose: breathe for the patient. Mechanism: a ventilator moves air in and out until neuromuscular function returns. Medscape

3. Sedation/analgesia while paralyzed.
   Purpose: prevent awareness and distress. Mechanism: sedative drugs ensure comfort until paralysis resolves. Medscape

4. Quantitative TOF/neuromuscular monitoring.
   Purpose: track depth of block and readiness for extubation. Mechanism: electrical stimulation measures twitch response as muscles recover. OpenAnesthesia

5. Avoidance of triggering drugs in the future.
   Purpose: prevent recurrence. Mechanism: do not use succinylcholine or mivacurium in known/suspected deficiency. NCBI

6. Use of alternative local anesthetics.
   Purpose: safe anesthesia for minor procedures. Mechanism: prefer amide local anesthetics (e.g., lidocaine) because ester anesthetics (e.g., procaine) depend on pseudocholinesterase. ekja.org

7. Post-op ICU/PACU observation.
   Purpose: watch for hypoventilation and hypoxemia. Mechanism: continuous monitoring detects problems early. Medscape

8. Family counseling and testing.
   Purpose: identify relatives at risk. Mechanism: dibucaine number or genetic testing guides safe anesthesia planning. OpenAnesthesia+1

9. Medical alert identification.
   Purpose: warn future clinicians. Mechanism: bracelets/cards state “pseudocholinesterase deficiency—avoid succinylcholine/mivacurium.” NCBI

10. Document anesthetic allergy list/electronic flags.
    Purpose: system-level prevention. Mechanism: EHR alerts when high-risk drugs are ordered. NCBI

11. Pre-operative anesthesia consultation.
    Purpose: risk stratification and plan alternatives. Mechanism: review history of prolonged apnea and order dibucaine number if needed. OpenAnesthesia

12. Stop cholinesterase-inhibiting eye drops (echothiophate) before elective surgery.
    Purpose: improve enzyme activity. Mechanism: remove a reversible inhibitor in advance. (Timing individualized.) NCBI

13. Avoid organophosphate exposure.
    Purpose: prevent further enzyme inhibition. Mechanism: organophosphates irreversibly inhibit pseudocholinesterase. NCBI

14. Optimize nutrition/liver health.
    Purpose: support enzyme production. Mechanism: BCHE is made in the liver; treat malnutrition and liver disease where possible. NCBI

15. Careful choice of muscle relaxants for rapid-sequence induction.
    Purpose: safe intubation when aspiration risk is high. Mechanism: use rocuronium at higher dose with planned reversal by sugammadex, not succinylcholine. accessdata.fda.gov+1

16. Standard aspiration precautions.
    Purpose: avoid complications while paralyzed. Mechanism: head-up positioning, suction, and cuffed tube protect airway. Medscape

17. Ventilator weaning only after objective recovery.
    Purpose: prevent re-paralysis and re-intubation. Mechanism: require TOF ratio ≥0.9 and strong clinical signs. OpenAnesthesia

18. Education for patients and caregivers.
    Purpose: empower safe care. Mechanism: teach which drugs to avoid and to inform all future clinicians. NCBI

19. Report prior adverse anesthetic events in all pre-op forms.
    Purpose: trigger testing and safe planning. Mechanism: early disclosure changes drug choices. OpenAnesthesia

20. Consider FFP in exceptional cases with severe, persistent block.
    Purpose: supply the missing enzyme when recovery is dangerously slow. Mechanism: transfused plasma provides pseudocholinesterase, accelerating drug breakdown; most cases do not require it. Medscape

---

Drug treatments

Important: Drugs do not “fix” the BCHE enzyme. They either reverse a compatible blocker, support physiology, or serve as safer alternatives. Below are the most relevant medicines used around this condition. (Doses are adult starting points from labels; clinicians individualize.)

1. Sugammadex (BRIDION).
   Class: Selective relaxant binding agent. Dose/Time: 2–4 mg/kg for routine reversal; 16 mg/kg for immediate reversal of high-dose rocuronium; effect within minutes. Purpose/Mechanism: Encapsulates rocuronium/vecuronium molecules and removes them from the neuromuscular junction to restore muscle function. Side effects: bradycardia, hypersensitivity, residual blockade if underdosed; dosing based on depth of block. accessdata.fda.gov+1

2. Rocuronium (ZEMURON / rocuronium bromide injection).
   Class: Non-depolarizing neuromuscular blocker (alternative to succinylcholine). Dose: 0.6 mg/kg typical intubating dose; higher doses (e.g., 1.0–1.2 mg/kg) for rapid-sequence when reversal by sugammadex is planned. Purpose/Mechanism: Competitive acetylcholine receptor blocker without dependence on BCHE for metabolism. Side effects: hypotension, tachycardia, anaphylaxis (rare). accessdata.fda.gov+1

3. Cisatracurium (NIMBEX).
   Class: Non-depolarizing blocker. Dose: Label provides intubation and infusion dosing; undergoes Hofmann elimination (organ-independent). Purpose/Mechanism: Good choice in liver/kidney disease; not metabolized by BCHE. Side effects: hypotension, bradycardia; caution in ICU infusions. accessdata.fda.gov

4. Vecuronium (representative non-depolarizing blocker).
   Class: Aminosteroid neuromuscular blocker. Use: Alternative to succinylcholine; reversible with sugammadex or neostigmine. Mechanism: Competitive block; not BCHE-dependent. Label: Standard cautions about prolonged paralysis and need for monitoring. accessdata.fda.gov

5. Neostigmine (BLOXIVERZ).
   Class: Acetylcholinesterase inhibitor used with glycopyrrolate. Dose: Label provides weight-based dosing near the end of case when some spontaneous recovery is present. Purpose/Mechanism: Increases acetylcholine at the neuromuscular junction to out-compete non-depolarizing blockers (not effective for succinylcholine-induced phase-I block). Side effects: bradycardia, bronchospasm, secretions (countered by glycopyrrolate/atropine). accessdata.fda.gov+1

6. Glycopyrrolate (with neostigmine).
   Class: Antimuscarinic. Purpose/Mechanism: Counters neostigmine’s muscarinic effects (bradycardia, secretions). Use: Standard pairing during reversal. Label: Anticholinergic effects and dosing guidance. accessdata.fda.gov

7. Atropine.
   Class: Antimuscarinic. Purpose: Treats bradyarrhythmias sometimes seen with succinylcholine or reversal. Mechanism: Blocks vagal effects on the heart. Label: ACLS-compatible dosing; monitor for tachycardia. accessdata.fda.gov

8. Succinylcholine (for context—to avoid in BCHE deficiency).
   Class: Depolarizing blocker. Label Warnings: Can cause prolonged apnea in people with atypical pseudocholinesterase; avoid if deficiency is known or suspected. Mechanism: Persistent depolarization at NMJ; requires BCHE for rapid breakdown. Side effects: hyperkalemia, bradyarrhythmias, malignant hyperthermia trigger in susceptible patients. accessdata.fda.gov+1

9. Mivacurium (MIVACRON—avoid in BCHE deficiency).
   Class: Non-depolarizing benzylisoquinolinium that also relies on pseudocholinesterase; deficiency prolongs block. Label: Duration increased with low enzyme activity. Side effects: histamine release at higher doses. accessdata.fda.gov+1

10. Atracurium (class example).
    Class: Non-depolarizing; partly Hofmann elimination/ester hydrolysis (not BCHE-dependent like succinylcholine). Purpose: Alternative in patients with BCHE deficiency. Label: Hypotension/flushing possible. accessdata.fda.gov

11. Pancuronium (class example).
    Class: Long-acting non-depolarizing blocker; avoid if rapid recovery is needed. Purpose: Historical agent; demonstrates options besides succinylcholine/mivacurium. Label: Vagal blockade, tachycardia. accessdata.fda.gov

12. Sedatives (e.g., propofol, midazolam) during paralysis.
    Class: Anesthetic/benzodiazepine. Purpose: Ensure comfort and amnesia while ventilated. Mechanism: CNS depression; not related to BCHE. Label: Standard warnings about respiratory depression (managed because patient is ventilated). Medscape

13. Opioid analgesics (e.g., fentanyl) as needed.
    Purpose: Pain control while paralyzed/ventilated. Mechanism: μ-opioid receptor agonism. Label: Respiratory depression (irrelevant during full ventilation, but still monitored). Medscape

14. Vasopressors (phenylephrine/ephedrine) if hypotension occurs.
    Purpose: Maintain blood pressure during prolonged anesthesia. Mechanism: α-adrenergic support or mixed action. Label: Standard dosing cautions. Medscape

15. Antiemetics (ondansetron) post-op.
    Purpose: Reduce nausea/vomiting risk during delayed emergence. Mechanism: 5-HT₃ blockade. Label: QT caution. Medscape

16. Bronchodilators if bronchospasm occurs (albuterol).
    Purpose: Optimize ventilation. Mechanism: β₂-agonism relaxes airway smooth muscle. Label: Standard inhaled dosing. Medscape

17. Reversal timing guided by TOF and PTC.
    Purpose: Avoid residual paralysis. Mechanism: Dose sugammadex/neostigmine against measured depth of block per label. accessdata.fda.gov

18. Avoid ester local anesthetics (e.g., procaine, chloroprocaine).
    Reason: They depend on pseudocholinesterase and can have prolonged effect in deficiency. Use amide agents instead. ekja.org

19. Careful drug interaction review (echothiophate, organophosphates).
    Purpose: Remove reversible inhibitors that worsen deficiency. Mechanism: Prevent further enzyme suppression. NCBI

20. Consider plasma (FFP) in rare, severe, prolonged block.
    Purpose/Mechanism: Provides exogenous pseudocholinesterase to metabolize remaining drug more quickly; used selectively. Medscape

Drug treatments

1. Succinylcholine (ANECTINE) — drug to avoid: Depolarizing NMBA that depends on BCHE; in deficiency it causes prolonged paralysis/apnea. Dose (for context): ~1 mg/kg IV for intubation. Mechanism: depolarizes motor endplate. Key risk: markedly prolonged block in BCHE deficiency—avoid in known cases. FDA Access Data+1

2. Mivacurium (MIVACRON) — drug to avoid: Non-depolarizing NMBA hydrolyzed by BCHE; may cause prolonged block/apnea in deficiency—avoid. Label note: metabolized by plasma cholinesterase. FDA Access Data+1

3. Rocuronium (ZEMURON): Preferred NMBA alternative. Typical dose: 0.6–1.2 mg/kg IV for intubation. Purpose: paralysis not dependent on BCHE. Mechanism: competitive ACh receptor blocker; hepatic/biliary elimination. Notes: predictable with monitoring. FDA Access Data+1

4. Sugammadex (BRIDION): Reversal agent for rocuronium/vecuronium. Dose: 2 mg/kg (TOF reappearance of 2 twitches), 4 mg/kg (1–2 PTC), 16 mg/kg for immediate reversal after 1.2 mg/kg rocuronium. Mechanism: encapsulates NMBA molecules. Benefit: rapid recovery of breathing. Common effects: taste disturbance, cough, nausea. FDA Access Data+1

5. Vecuronium: Non-depolarizing NMBA option. Use: paralysis not reliant on BCHE; reversible with sugammadex or neostigmine. Notes from FDA materials: labeled for surgical relaxation; dose individualized. FDA Access Data

6. Cisatracurium (NIMBEX): Non-depolarizing NMBA broken down by Hofmann elimination (organ-independent). Use: good in liver disease. Dose: per label; titrate with monitoring. Adverse effects: bradycardia/hypotension rare. FDA Access Data

7. Atracurium (class note): Similar to cisatracurium with Hofmann/ester hydrolysis (not BCHE-dependent). Use: alternative paralytic. Mechanism: non-depolarizing blockade. (Label references within NMBA reviews.) NCBI

8. Pancuronium: Long-acting non-depolarizing NMBA; avoid for short cases but not BCHE-dependent. Mechanism: competitive block. Note: bradycardia less common; watch for tachycardia. (NMBA overview) NCBI

9. Neostigmine (BLOXIVERZ): Reverses non-depolarizing NMBAs when some recovery is present; Dose: ~0.04–0.07 mg/kg IV with antimuscarinic (glycopyrrolate). Mechanism: acetylcholinesterase inhibition increases ACh. Effects: bradycardia; give with glycopyrrolate or atropine. FDA Access Data+1

10. Glycopyrrolate (GLYRX-PF / generics): Antimuscarinic used with neostigmine to prevent bradycardia/secretions. Dose: ~0.01 mg/kg IV with neostigmine. Mechanism: blocks muscarinic receptors. Effects: dry mouth, tachycardia. FDA Access Data+1

11. Atropine: Alternative antimuscarinic with neostigmine; also treats severe bradycardia. Mechanism: muscarinic blockade. Label: indicated for bradyasystolic cardiac arrest and antisialagogue use. FDA Access Data+1

12. Midazolam (injection): Sedation while ventilated. Mechanism: GABA-A modulation. Label guidance: titrate to effect; use lowest effective dose with residual anesthetics. FDA Access Data

13. Propofol: Sedation/induction agent while mechanically ventilated. Mechanism: GABAergic; short-acting. Use: comfort during prolonged paralysis. (Standard anesthetic practice review) NCBI

14. Fentanyl: Opioid analgesia during ventilated support when needed. Mechanism: μ-opioid agonist; titrate carefully with monitoring. (NMBA/anesthesia overviews) NCBI

15. Ketamine: Induction/analgesia with preserved airway reflexes; useful if bronchodilation needed. Mechanism: NMDA antagonism. Note: clinician-selected adjunct. (Anesthesia overviews) NCBI

16. Etomidate: Hemodynamically stable induction agent if repeated intubation is needed without succinylcholine. Mechanism: GABA-A modulation. (Anesthesia references) NCBI

17. Lidocaine (amide local): Local anesthesia option not dependent on BCHE. Mechanism: sodium-channel block; hepatic metabolism. Use: safer than ester locals in BCHE deficiency. MedlinePlus

18. Dexamethasone: Antiemetic/anti-inflammatory to improve recovery comfort (not specific to BCHE). Mechanism: glucocorticoid. (ERAS elements) PMC

19. Ondansetron: Antiemetic to reduce PONV while recovering. Mechanism: 5-HT3 blockade. (ERAS elements) PMC

20. Sugammadex (pediatric update): Label updated to include infants <2 years (reversal for roc/vec). Relevance: supports broad use when avoiding succinylcholine. FDA Access Data

Important: Items 1–2 show the drugs to avoid in BCHE deficiency. Items 3–20 are part of safe anesthetic care instead of succinylcholine/mivacurium; all must be prescribed and titrated by anesthesia professionals.

---

Dietary molecular supplements (supportive, not curative)

There is no supplement proven to “fix” BCHE deficiency or shorten succinylcholine/mivacurium paralysis. Nutrition matters mainly to support liver protein production and overall recovery. The points below reflect perioperative nutrition science; use only with clinician approval:

1. Adequate protein intake — Supports liver synthesis of plasma proteins (including BCHE) and wound healing after surgery. Mechanism: amino acids for hepatic protein production. SpringerLink

2. Pre-op carbohydrate drink (when allowed) — Part of ERAS; can reduce surgical stress and improve comfort. Mechanism: blunts insulin resistance from fasting and surgery. PMC+1

3. Vitamin D (if deficient) — General immune and muscle health; correct deficiency identified by tests. Mechanism: nuclear receptor effects; not BCHE-specific. (ERAS nutrition summaries) ASPEN

4. Omega-3 fatty acids — May support anti-inflammatory balance in recovery, guided by dietitian. Mechanism: eicosanoid profile shift. (Perioperative nutrition literature) ASPEN

5. Multivitamin with B-complex (if diet is poor) — Addresses malnutrition that can lower enzyme levels. Mechanism: broad micronutrient support for hepatic synthesis. SpringerLink

6. Zinc (if low) — Supports wound healing and immunity; test-guided. Mechanism: cofactor in protein synthesis/repair. (Perioperative nutrition guidance) ASPEN

7. Iron (if deficient) — Treat iron-deficiency anemia to improve recovery capacity. Mechanism: hemoglobin/oxygen transport; test-guided. (ERAS nutrition) ASPEN

8. Vitamin C — Antioxidant that supports collagen synthesis and wound healing; avoid megadoses. Mechanism: cofactor for prolyl/lysyl hydroxylase. (Nutrition guidance) ASPEN

9. Arginine-containing oral nutrition supplements (ONS) when indicated — Sometimes used in surgical patients to support immune function. Mechanism: nitric oxide/immune modulation. (ERAS nutrition statements) ASPEN

10. Thiamine (if depleted) — In malnourished or alcohol-use patients to support energy metabolism. Mechanism: carbohydrate metabolism coenzyme. (Perioperative nutrition) ASPEN

Again, these are general recovery supports—none specifically reverse BCHE-related paralysis, and all should be dietitian/clinician-guided. ASPEN

---

Immunity-booster / Regenerative / Stem-cell drugs

There are no approved regenerative or stem-cell drugs to treat BCHE deficiency. Experimental work uses purified or recombinant human butyrylcholinesterase as a “bioscavenger” for nerve agents, not for routine anesthesia care. This remains investigational. PMC+1

1. Human plasma-derived BCHE (investigational) — Function: supplies exogenous enzyme; studied mainly to neutralize organophosphates. Mechanism: stoichiometric binding/hydrolysis of toxic esters. Status: research/early clinical safety; not standard for post-anesthetic apnea. ScienceDirect

2. Recombinant human BCHE (investigational) — Function: lab-made enzyme as long-acting bioscavenger. Mechanism: binds/neutralizes ester toxins; engineered for longer half-life. Status: preclinical/early clinical; not routine care. PMC+1

3. Long-acting rBCHE fusion constructs (investigational) — Function: albumin-fused or multimeric BCHE to extend circulation. Mechanism: slower clearance increases protective window. Status: preclinical. BioMed Central

4. Transgenic-source BCHE (investigational) — Function: BCHE produced in animals or plants; proof-of-concept for scalable supply. Mechanism: biologic manufacturing approach. Status: research only. PNAS+1

5. Commercial serum cholinesterase (historical/limited access) — Function: exogenous enzyme used in case reports to hasten recovery. Mechanism: increases plasma hydrolysis of succinylcholine. Status: rarely available; not guideline-recommended. mathewsopenaccess.com

6. Fresh Frozen Plasma (supportive, not “regenerative”) — Function: adds BCHE transiently; sometimes used in reports. Mechanism: donor BCHE activity. Status: inconsistent benefit; not routine because of transfusion risks. Orphan Anesthesia+1

---

Surgeries

BCHE deficiency itself does not require surgery. These are common operations where anesthesia planning must change to keep you safe:

1. Emergency airway/intubation — Occurs when breathing stops post-anesthesia; not a treatment for BCHE but a lifesaving procedure. Why done: to ventilate until recovery. Medscape

2. Any elective surgery in future — The “procedure” here is a modified anesthetic plan (no succinylcholine/mivacurium; use rocuronium ± sugammadex). Why done: prevention. NCBI+1

3. Regional/neuraxial anesthesia — Chosen instead of general anesthesia when suitable. Why done: avoid neuromuscular blockers altogether. NCBI

4. Airway protection procedures (e.g., bronchoscopy for aspiration) — Only if complications occur. Why done: treat aspiration or mucus plugging. Medscape

5. ICU protocols for extubation readiness — A “procedure” set that ensures safe tube removal after monitoring proves recovery. Why done: prevent re-intubation. NCBI

---

Preventions

1. Tell every clinician you have (or might have) pseudocholinesterase deficiency. Wear a medical alert. NCBI

2. Avoid succinylcholine and mivacurium for all future anesthetics. NCBI

3. Use alternatives (e.g., rocuronium with sugammadex, cisatracurium). accessdata.fda.gov+1

4. Ask for pre-op anesthesia consult and note any past prolonged paralysis. OpenAnesthesia

5. Consider dibucaine number or BCHE genetic testing if history suggests risk. OpenAnesthesia+1

6. Review eye drops/chemicals (echothiophate, organophosphates) before surgery. NCBI

7. Optimize liver health and nutrition where possible. NCBI

8. Plan quantitative neuromuscular monitoring during anesthesia. OpenAnesthesia

9. Share family history; advise relatives to be tested if appropriate. OpenAnesthesia

10. Document prominently in your medical record and patient portal. NCBI

---

When to see a doctor

See an anesthesiologist or pre-operative clinic before any procedure that might use anesthesia if you have a personal or family history of prolonged apnea, unexpected delayed waking, or ventilation after surgery. Seek urgent care after any anesthesia if you notice severe weakness, trouble breathing, low oxygen, or frequent choking. For planned surgeries, arrange a pre-op plan to avoid succinylcholine/mivacurium, choose safe alternatives, and set up monitoring and reversal as needed. NCBI+1

---

What to eat and what to avoid

There is no special diet that treats BCHE deficiency or prevents post-anesthetic apnea. Eat a balanced diet and follow your clinician’s usual pre-op fasting rules (stop solid food at the advised time; clear liquids until the allowed cutoff). Avoid alcohol the day before surgery and do not take unapproved supplements right before an operation, as they can interact with anesthesia. Focus on sharing your medication and supplement list with the anesthesia team rather than specific foods. NCBI

---

FAQs

1) Why did I stop breathing after anesthesia?
Because your body could not break down a muscle relaxant (most often succinylcholine or mivacurium) quickly due to low or abnormal pseudocholinesterase enzyme. NCBI

2) Is this rare?
Yes. Many people only discover it after an unexpected prolonged paralysis post-op. NCBI

3) Is it genetic?
Often yes. Changes in the BCHE gene cause inherited forms; family members may also be at risk. MedlinePlus

4) Can illnesses or medicines cause it?
Yes. Pregnancy, liver disease, malnutrition, organophosphates, and some drugs can lower enzyme levels. NCBI

5) Which drugs are the main problem?
Succinylcholine and mivacurium. Avoid them if deficiency is known or suspected. accessdata.fda.gov+1

6) What are safe alternatives?
Rocuronium (with sugammadex reversal), cisatracurium, vecuronium, or atracurium, chosen by the anesthesiologist. accessdata.fda.gov+2accessdata.fda.gov+2

7) How is it diagnosed?
By history, low enzyme level, low dibucaine number, and sometimes BCHE gene testing. OpenAnesthesia+1

8) What happens during treatment?
You receive ventilation and oxygen until the drug effect wears off or is reversed; you are kept comfortable and sedated. Medscape

9) How long until I breathe on my own?
It varies from minutes to hours, depending on the drug and enzyme activity; monitoring guides safe extubation. Medscape

10) Do I need plasma transfusion?
Usually no. Most recover with supportive care; FFP is reserved for unusual, very prolonged cases. Medscape

11) Should I carry a medical alert?
Yes. This prevents accidental use of the risky drugs in emergencies. NCBI

12) Do local dental anesthetics matter?
Prefer amide local anesthetics. Ester local anesthetics can last longer in BCHE deficiency. Tell your dentist. ekja.org

13) Will this affect pregnancy or C-section anesthesia?
Pregnancy lowers enzyme levels. Your obstetric and anesthesia teams should plan to avoid succinylcholine/mivacurium. NCBI

14) Can I ever have general anesthesia again?
Yes—with a clear plan using safe alternatives and monitoring. OpenAnesthesia

15) Can diet or vitamins fix this?
No. This is an enzyme/drug issue, not a vitamin deficiency. Prevention is by drug choice and care plan. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 07, 2025.